Multiple Sclerosis Clinical Trial
— FERLAMSOfficial title:
The Feasibility and Efficacy of a Remotely Delivered Exercise Training Intervention for the Hispanic/Latino Community With Multiple Sclerosis
The goal of this clinical trial is to investigate the potential benefits of a specially designed exercise program for Hispanics/Latinos with multiple sclerosis (MS). The main questions it aims to answer are: - Can a 4-month remotely-delivered exercise training program improve physical function, symptom management, and quality of life in Hispanics/Latinos with MS? - How do social determinants of health, such as income, education, access to healthcare, and social support, influence the feasibility and effectiveness of the exercise intervention? Participants in this study will engage in a 4-month remotely-delivered exercise training intervention that includes flexibility, or aerobic and resistance exercise training sessions. They will work with experienced coaches who will guide and support them throughout the program. The researchers will compare the participants who receive the exercise intervention with a control group to see if the exercise program leads to significant improvements in physical function, fatigue, mood, and overall well-being for Hispanics/Latinos with MS. The study aims to empower this underserved population and provide insights for future healthcare and research initiatives.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | July 31, 2025 |
Est. primary completion date | May 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age between 18-65 years - Diagnosis of MS - Relapse-free for at least 30 days - Able to walk with or without an assistive device - Insufficient physical activity (i.e., not meeting current physical activity guidelines of 150 minutes of moderate to vigorous physical activity per week) - Willingness to complete all required testing procedures, outcome questionnaires, and randomization - Identify as Hispanic/Latino - Able to speak, read, and understand English - Currently reside in Chicago - Access to the internet and email - Safe for exercise based on the Physical Activity Readiness Questionnaire (PAR-Q) Exclusion Criteria: - Not between 18-65 years - No diagnosis of MS - Not relapse-free for at least 30 days - Not able to walk with or without an assistive device - Too much physical activity (i.e. 150 minutes or more of moderate to vigorous physical activity per week) - Not willing to complete all required testing procedures, outcome questionnaires, and randomization - Do not identify as Hispanic/Latino - Unable to speak, read, and understand English - Not currently residing in Chicago - No access to the internet and email - Not safe for exercise based on the PAR-Q |
Country | Name | City | State |
---|---|---|---|
United States | University of Illinois at Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Social Determinants of Health Factors | Assessed with the PhenX Toolkit, a consensus measurement for phenotypes and exposures in human research (Cox et al., 2021). Individual SDOH will assess 12 factors (access to health services, health technology, prescription affordability, discrimination in health care, English proficiency, health literacy, job insecurity, neighborhood environment, racial/ethnic discrimination, religious behaviors, spirituality, and wealth), and structural SDOH factors will assess 7 factors (educational attainment, social vulnerability, neighborhood walking and biking environment, water access and sanitation, air quality index, concentrated poverty, and food). | Before and after 16 weeks, baseline and post-intervention | |
Primary | Process: Participant Recruitment and Retention | Assessed by recruitment and refusal rates, and retention, attrition, and adherence rates. This will be monitored and assessed with USPS, phone, and electronic mail recruitment, and record all contact with potential participants and refusal reasons. Participants' flow through recruitment, enrollment, and intervention will be monitored, and adherence will be assessed with log books, zoom assessments, and time spent in physical activity as measured during follow-up assessment. | Before, During, and After 16 weeks, pre-, intra- and post-Intervention | |
Primary | Resources: Communication and Monetary Requirements of the Study | Assessed by communication with participants and staff (needs), and monetary costs of research. This will be monitored and assessed with data collected on initial and follow-up contact with all potential and enrolled participants. A record of all problems and communication alterations will be monitored, as well as all monetary costs for the study that includes both the intervention and control groups. | Before, During, and After 16 weeks, pre-, intra- and post-Intervention | |
Primary | Management: Data Management and Safety Reporting During the Study | Assessed by IRB approval procedures, staff preparation and report time for participant communication, time and accuracy in data collection/entry, and reporting and handling of adverse events, serious adverse events, and clinical emergencies. All communications between University IRB and staff, and time from submission of IRB application to approval will be documented. All preparation, call time, attempted call time and report-taking time for each participant during the intervention will be documented. Data completeness, time to record completeness, time to record, enter, and check data will be monitored, and use and handling of all standard university protocol for reporting of all adverse events, serious adverse events, and clinical emergencies will be recorded. | During and After 16 weeks, intra- and post-Intervention | |
Primary | Scientific: Safety, Burden and Treatment Effect of the Study | Assessed by adverse events, serious adverse events, and clinical emergencies, participants' experience, burden, and compliance during the intervention, and treatment effect. Standard university protocol to record all adverse events, serious adverse events, and clinical emergencies will be followed, and participants will be asked to report all medical concerns for staff to record via log books and zoom chats. Effect size and clinical meaningfulness of any change in physical activity, sedentary behavior, symptoms, and health-related quality of life outcomes will be measured. | During and After 16 weeks, intra- and post-Intervention | |
Secondary | Lower Extremity Function | Assessed by the 30-Second Sit to Stand Test (30STS). The score is the number of complete repetitions of sit-to-stand movements performed for 30 seconds; the minimum value is 0 repetitions, and the maximum value depends on individuals' performance. Higher scores reflect better lower extremity function. | Before and after 16 weeks, baseline and post-intervention | |
Secondary | Visual Processing Speed | Assessed by the Symbol Digit Modalities Test (SDMT). Participants will verbally identify digit-symbol pairings as quickly as possible in response to a series of unpaired symbols displayed on screen. The outcome is the total number of correct responses in 30, 60 and 90 seconds. | Before and after 16 weeks, baseline and post-intervention | |
Secondary | Verbal Learning and Memory | Assessed by the California Verbal Learning Test II (CVLT-II). Participants will be read aloud 16 words and immediately recall as many words as possible, in any order, for each of the five trials. The total score out of 80 will be calculated by summing the number of correct responses from each trial (T1 to T5). | Before and after 16 weeks, baseline and post-intervention | |
Secondary | Fatigue Severity | Assessed by the Fatigue Severity Scale (FSS); scores range between 1 (min) and 7 (max), higher scores reflect greater fatigue severity. | Before and after 16 weeks, baseline and post-intervention | |
Secondary | Depressive Symptoms | Assessed by the Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms. | Before and after 16 weeks, baseline and post-intervention | |
Secondary | Exercise Behavior | Assessed by Godin Leisure-Time Exercise Questionnaire (GLTEQ); scores range between 0 (min) and 119 (max), higher scores indicate greater engagement in exercise behavior. | Before and after 16 weeks, baseline and post-intervention | |
Secondary | Health-related Quality of Life | Assessed by the Short Form -12 (SF-12), a shortened version of the short-form 36-item health survey, which measures overall health status.The component scores are adjusted based on a relative average, where a score above 50 is considered above average and a score below 50 is considered below average. | Before and after 16 weeks, baseline and post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |